|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rapid detection of genotypes and mutation in the pre - core promoyer and the pre - core region of hepatitis B virus genome: correlation with viral persistence and disease severity显示文摘 | Grandjecques C Pradat P Stuyer L | 2000 | J Hepatol2000，33，3： | 1 |
| 2 | Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study显示文摘 | Si-Ahmed SN Pradat P Zoutendijk R | 2011 | Antiviral Res2011，92，1： | 1 |
| 3 | Rapid detection of genotypes and mutations in the pre-core and the pre-core region of hepatitis B virus genorne显示文摘 | Kidd-Ljunggren K Grandjacquesc P Pradat P | 1997 | J Gen Virol1997，78，： | 1 |
| 4 | Causes of death in a post- mortem series of ALS patients 显示文摘 | Corcia P Pradat PF Salachas F | 2008 | Amyotroph Lateral Scler2008，9，1： | 1 |
| 5 | Treatment of peripheral neuropathies with neutrotrophic factors: animal models and clinical trials 显示文摘 | Pradat PF | 2003 | Rev Neurol (Paris)2003，159，2： | 1 |
| 6 | Abnormalities of satellite cells function in amyotrophic lateral sclerosis显示文摘 | Pradat PF Barani A Wanschitz J | | 0，，04： | 1 |
| 7 | Continuous delivery of neuortorphin 3 by gene therapy has a neuorportective effect in experimental models of diabetic and acrylarnide neu ropathies 显示文摘 | Pradat PF Kennel P N aimi-Sadaoui S | 2001 | Hum Gene Ther2001，12，18： | 1 |
| 8 | The epidemiology of cardio- vascular defects part I : a study based on data from three large regis- tries of congenital malformations 显示文摘 | Pradat P Franeannet C Harris JA | 2003 | Pediatr Cardol2003，24，3： | 1 |
| 9 | Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy显示文摘 | Pradat PF Kennel P Naimi-Sadaoui S | 2002 | Gene Ther2002，9，19： | 1 |
| 10 | Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients response to therapy显示文摘 | Maynard M Pradat P Berthillon P | | 0，，： | 1 |
| 11 | Long-term follow-up of the hepati- tis C HENCORE cohort:response to therapy and occurrence of liver- related complications 显示文摘 | Pradat P Tillmann HL Sauleda S | 2007 | J Viral Hepat2007，14，8： | 1 |
| 12 | Neuroflament light and heterogeneity of disease progression in amyotrophic lateral sclerosis:development and validation of a prediction model to improve interventional trials显示文摘Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014. | Simon Witzel Felix Frauhammer† Petra Steinacker David Devos Pierre‑François Pradat Vincent Meininger Stefen Halbgebauer Patrick Oeckl Joachim Schuster Simon Anders Johannes Dorst Markus Otto Albert C.Ludolph | 2021 | Translational Neurodegeneration2021，10，3： | 1 |
| 13 | A rare disease but a classic ALS mimic syndrome显示文摘 | Pierre-Francois Pradat T | 2014 | Sclerose lateraleamyotrophique2014，43，5： | 1 |
| 14 | Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B显示文摘 | Koffi J Egounlety R Pradat P | 2014 | Eur J Gastroenterol Hepatol2014，26，2： | 1 |
| 15 | Radiation-induced neuropathy in cancer survivors 显示文摘 | Delanian S Lefaix JL Pradat PF | 2012 | Radiother Oncol2012，105，3： | 1 |
| 16 | Synthesis of Sulfones by phase-transfer alkylation of arenesulfinate salts显示文摘 | Jack K Crandall Chrostian Pradat | 1985 | J Org Chem1985，50，8： | 1 |
| 17 | Predictive value of ALT levels for histologic findings in chronic hepatitis C:a European collaborative study显示文摘 | Pradat P Alberti A Poynard T | 2002 | Hepatology2002，36，： | 1 |
| 18 | Late radiation injury to peripheral nerves 显示文摘 | Pradat PF Delanian S | 2013 | Handb Clin Neural2013，115，： | 1 |
| 19 | Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence‐based review with good practice points. EALSC Working Group显示文摘 | Peter Munch Andersen Gian Domenico Borasio Reinhard Dengler Orla Hardiman Katja Kollewe Peter Nigel Leigh Pierre‐Francois Pradat Vincenzo Silani Barbara Tomik | 2007 | Amyotrophic Lateral Sclerosis2007，，4： | 1 |
| 20 | Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome:correlation with viral persistence and disease severity显示文摘 | Grandjacques C Pradat P Stuyver L | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员